Abstract |
10 patients with CLL and 2 with CML were treated with gradually increasing doses of 1 alpha( OH)D3, up to 4 micrograms daily during 6 wk. 3 patients with preleukemia and 1 with myelofibrosis were treated with 2 micrograms daily of 1 alpha( OH)D3 for a prolonged period up to 17 wk. The treatment with 1 alpha ( OH)D3 did not result in changes of disease parameters in any of the patients under study. Receptor studies for 1,25(OH)2D3 were performed in 8 CLL patients and revealed only 1 patient with increased specific receptor binding capacity. The maximum tolerable dose of 1 alpha( OH)D3 varied individually, but was in the range of 2-4 micrograms daily.
|
Authors | S B Wieslander, B T Mortensen, L Binderup, N I Nissen |
Journal | European journal of haematology
(Eur J Haematol)
Vol. 39
Issue 1
Pg. 35-8
(Jul 1987)
ISSN: 0902-4441 [Print] England |
PMID | 3477470
(Publication Type: Journal Article)
|
Chemical References |
- Hydroxycholecalciferols
- Receptors, Drug
- alfacalcidol
|
Topics |
- Humans
- Hydroxycholecalciferols
(metabolism, therapeutic use)
- Leukemia, Lymphoid
(blood, drug therapy, pathology)
- Leukemia, Myeloid
(blood, drug therapy, pathology)
- Lymphocytes
(ultrastructure)
- Myeloproliferative Disorders
(blood, drug therapy, metabolism)
- Receptors, Drug
(metabolism)
|